Soluble cytokeratin fragment 19 levels were measured with an enzyme immunoassay method developed by Boehringer Mannheim (Enzymun-Test CYFRA 21-1) in the serum of 185 patients with lung cancer [149 with non-small-cell lung cancer (NSCLC) and 36 with small-cell lung cancer (SCLC)] and 97 patients with benign lung diseases in order to determine its clinical usefulness in the diagnosis of lung cancer and follow-up of treatment. We used the cut-off value of 3.5 ng ml'. established by the Japan CYFRA research group. This cut-off value is based on calculations using the receiver operating characteristic approach instead of using the 95% specificity approach recommended by other authors. The resulting sensitivity and specificity for the group of all lung cancer patients were 65.4% and 84.5% respectively. The sensitivity was highest (76.1%) for squamous cell carcinoma and lowest (44.4%) for SCLC. For NSCLC patients, when CYFRA 21-1 levels were analysed by node (N) factor, patients who presented with mediastinal lymph node metastasis (N2 or N3) demonstrated higher serum CYFRA 21-1 levels (5.6; interquartile range 3.2-11.5ng ml-1) than patients without mediastinal node metastasis (NO or Nl, 3.9; interquartile range 2.2 -10.0 ng ml -; Mann -Whitney UI-test, P = 0.0373). We compared the discriminatory power of CYFRA 21-1 with that of other tumour markers including carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE). The area under the curve (AUC) of each ROC curve was calculated using the CLABROC program for statistical analysis. CYFRA 21-1 appeared to have the most discriminatory power of the markers tested in the diagnosis of lung cancer. In serial measurements of 14 patients receiving chemotherapy or radiotherapy, a high degree of correlation was noted between serum levels of CYFRA 21-1 and extent of clinical response (Wilcoxon, P= 0.0093).
Lung cancer is the commonest cause of death due to cancer in the world. Since non-small-cell lung cancer (NSCLC) accounts for the majority (70-80%) of all lung cancers, improvement in its treatment will have a major impact on both the rate of survival of lung cancer patients and the rate of survival of all cancer patients as a group. In contrast to other solid tumours, adequate assessment of follow-up and efficiency of therapy exists only for small-cell lung cancer (SCLC) by means of the determination of neuron-specific enolase (NSE) (Carney et al., 1982; Akoun et al., 1985) . None of the several serum components proposed as indicators of the extent of disease and clinical response to treatment appear to be sensitive or specific enough for general use in the management of the patients with NSCLC or as screening tools for early detection of disease.
All epithelial tissues, both normal and malignant (Moll et al., 1982; Osborn and Weber, 1982) , contain cytokeratins, which form the intermediate filament cytoskeleton within epithelial cells. This family of human cytokeratins consists of 19 different polypeptides, which have been numbered 1 -19 by Moll et al. (1982) . These cytokeratins are not randomly distributed in the various epithelia, but appear to be characteristic for certain types of epithelial differentiation (Hoefler and Denk, 1984) . Cytokeratin 19 is an acidic (type I) subunit expressed in all simple epithelia and in carcinomas such as lung cancer which arise from them (Broers et al., 1987 (Broers et al., , 1988 .
A fragment of cytokeratin subunit 19 can be measured in serum with a new enzyme immunoassay using two mouse MAb, Ks 19.1 and BM 19.21 (Bodenmuller et al., 1992) . This cytokeratin 19 fragment is referred to as CYFRA 21-1. The present study was undertaken to identify relationships between levels of this marker and other clinically significant vanables in patients with SCLC and NSCLC, and also to determine the usefulness of CYFRA 21-1 as a marker for follow-up in the treatment of lung cancer.
Materials and methods

Patients
This study was performed retrospectively using 185 consecutively obtained samples (Table I) (Metz, 1991) These data were analysed regarding optimal cut-off selection from two different viewpoints. First, a cut-off level of S.Sngml'--derived from 95% specificity in the benign group (Klapdor, 1992) was used; the resulting sensitivity is shown in Table II .
Alternatively, we applied the cut-off level definition recommended by the Japan CYFRA research group (Kawai et a?., 1993), using the ROC curve approach. The Japan CYFRA research group choose 3.5 ng ml-' as the cut-off because this level was closest to the upper left-hand corner of the ROC curve. This level is regarded as optimum in terms of making the fewest mistakes when prevalence is at or around 50% (Sackett et al., 1991) . In the case of the Japan CYFRA research group, the prevalenc was 54%. The results for sensitivity based on a cut-off level of 3.5ngml-' and spificity are shown in Table H . By using the cut-off definition based on the ROC curve (3.5 ng ml-'), a higher number of NSCLCs can be detected than when using the definition based on 95% specificity (5.5 ng ml-'). The resulting decrase in specificity from 95% to 84.5% when 3.5 ng ml' was used as the cut-off was accepted by the research group, because the main aim of the CYFRA 21-1 test is the early detection of NSCLC. Therefore, in the following, we focus on the cut-off level of 3.5 ng ml-' based on the ROC approach.
CYFRA 21-1 distribution and histological type of hlng cancer The median and interquartile ranges of serum CYFRA 21-1 values were significantly higher in cancer patients (respectively 4.9 and 2.7-10.7) than in control subjects (2.0 and 1.6-2.9; Mann-Whitney U test, P = 0.0001). As shown above, the sensitivity and specificity for the group of all lung cancer patients were 65.4% and 84.5% respectively, if a cut-off level of 3.5 ng ml-' was applied. The prevalence of elevated CYFRA 21-1 levels and the distribution of individual CYFRA 21-1 values are shown in Figure 1 . The median Torigoe, 1977) and NSE (RIA, Eiken. Japan; Notomi et al.. 1985) . with CYFRA 21-1 using our patient samples. Table III 21-1 and CEA levels during treatment. PR. partial response. NC (-) . no change. PD (---),
Changes in CYFRA 21-1 and CEA levels during treatment Determination of CYFRA 21-1 and CEA was performed serially (monthly) after the initial treatment in 14 patients ( Figure 6 ). Of ten patients who responded to treatment (six to chemotherapy, four to chemoradiotherapy), nine had remarkably large decreases in CYFRA 21-1 levels after the treatment (4-8 weeks) (Wilcoxon test, P = 0.0093), whereas CEA levels showed only a small decrease in five patients (Wilcoxon test, P = 0.4652). (Moll et al., 1982; Osborn and Weber 1982) , in contrast with the well-known phenotypic instability of cancer cells (Nicolson, 1987) . Antibodies raised against some antigenic deterninations common to all cytokeratins are, therefore, useful in typing poorly differentiated malignant tumours (Osborn and Weber, 1982 . : Gaast et al.. 1994 (Hansen et al.. 1980; Waalkes et al., 1980; Carney et al.. 1982) in patients with SCLC. However, in 2 out of 14 patients in whom CYFRA 21-1 was measured at earlier points in addition to 4-8 weeks there was a decrease in CYFRA 21-1. indicating a faster excretion of this marker. We therefore recently conducted a prospective trial to monitor this marker. In this study CYFRA 21-1 is measured frequently during the early period after treatment (including day 1). From this trial we will be able to determine tumour lysis.
According to McKenzie et al. (1977) the practical value of a tumour marker depends on three factors: the frequency with which the marker is detected in the tumour population, the correlation between the blood level of the marker and the tumour burden; and the availability of effective treatment for the tumour. The findings of our study suggest that measurement of CYFRA 21-1 meets these critenra for a tumour marker of use in screening and planning treatment for NSCLC.
